PhoreMost Ltd, a leading UK biopharmaceutical company unlocking the next generation of drug targets, has added USD $12 million to its Series B financing, bringing the total raised to over $50 million. The additional investment was led by Parkwalk Advisors, the largest growth EIS fund manager, with participation from existing investors BGF, Dr Jonathan Milner, Amadeus Capital and Astellas Venture Management, and will support the progression of PhoreMost's pipeline of novel degrader assets.